Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Arix Bioscience (Group)

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Led by renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has an office in New York. Our extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate finance puts us in an especially strong position to build and support a wide range of businesses and technologies. Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. We also have access to a broad range of research projects from US academic institutions. Fund Management Business Arthurian Life Sciences Ltd (ALS) is a wholly-owned subsidiary of Arix Bioscience plc and operates as the regulated investment manager of the Group. ALS is also the Manager of The Wales Life Sciences Investment Fund (WLSIF) and is authorised and regulated by the Financial Conduct Authority. UCB Strategic Relationships UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. Arix has a strategic agreement to provide to UCB reasonable access to its process of acquiring its Group Businesses, including participation in deal sourcing, deal screening and due diligence with a view to facilitating UCB’s investment in such Group Businesses in therapeutic areas including fields of immunology, neurology and bone, by establishing a joint advisory committee. *

 

Period Start 2017-02-02 existent
Products Industry venture capital
  Industry 2 LIFE SCIENCES
Persons Person Anderson, Joe (Arix Bioscience 201809– Chief Investment Officer before CEO before Abingworth)
  Person 2 Peacock, Jonathan M. (Jon) (Arix Bioscience 201805 Chairman before Amgen + Novartis Pharmaceuticals AG CFO + McKinsey)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 20 Berkeley Square
  City W1J 6EQ London
  Tel +44-20-7290-1050
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency GBP
  Annual sales 1,857,000 (revenue (2017) 2017-12-31)
  Profit -7,469,000 (2017-12-31)
  Cash 74,938,000 (2017-12-31)
     
    * Document for �About Section�: Arix Bioscience plc. (10/31/16). "Press Release: Arix Bioscience Appoints Dr Franz B. Humer as Senior Independent Director". London.
     
   
Record changed: 2021-03-15

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Arix Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top